Cardiac Amyloidosis – An Underdiagnosed Cause of Heart Failure with Preserved Ejection Fraction – Updated Diagnosis and Treatment Options

1 Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JCF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC scientific document group. Eur Heart J. 2016; 37:2129–200. PonikowskiP VoorsAA AnkerSD BuenoH ClelandJCF CoatsAJS FalkV Gonzalez-JuanateyJR HarjolaVP JankowskaEA JessupM LindeC NihoyannopoulosP ParissisJT PieskeB RileyJP RosanoGMC RuilopeLM RuschitzkaF RuttenFH van der MeerP ESC scientific document group Eur Heart J 2016 37 2129 200 10.1093/eurheartj/ehw12827206819 Search in Google Scholar

2 Bieske P, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancelloti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowsky P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitza F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). 2019; 40:3297–317. BieskeP TschopeC de BoerRA FraserAG AnkerSD DonalE EdelmannF FuM GuazziM LamCSP LancellotiP MelenovskyV MorrisDA NagelE Pieske-KraigherE PonikowskyP SolomonSD VasanRS RuttenFH VoorsAA RuschitzaF PaulusWJ SeferovicP FilippatosG How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) 2019 40 3297 317 10.1093/eurheartj/ehz64131504452 Search in Google Scholar

3 Triposkiadis F, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ, Backs J, BauerSachs J, Burkhoff D, Bonow RO, Chopra VK, de Boer RA, de Windt L, Hamdani N, Hasenfuss G, Heymans S, Hulot JS, Konstam M, Lee RT, Linke WA, Lunde IG, Lyon AR, Maack C, Mann DL, Mebazaa A, Mentz RJ, Nihoyannopoulos P, Papp Z, Parisiss J, Pedrazzini T, Rosano G, Rouleau J, Seferovic PM, Shah AM, Starling RC, Tocchetti CG, Trochu JN, Thum T, Zannad F, Brutsaert DL, Segers VF, De Keulenaer GW. The continuous heart failure spectrum: moving beyond an ejection fraction classification. Eur Heart J. 2019; 40:2155–63. TriposkiadisF ButlerJ AbboudFM ArmstrongPW AdamopoulosS AthertonJJ BacksJ BauerSachsJ BurkhoffD BonowRO ChopraVK de BoerRA de WindtL HamdaniN HasenfussG HeymansS HulotJS KonstamM LeeRT LinkeWA LundeIG LyonAR MaackC MannDL MebazaaA MentzRJ NihoyannopoulosP PappZ ParisissJ PedrazziniT RosanoG RouleauJ SeferovicPM ShahAM StarlingRC TocchettiCG TrochuJN ThumT ZannadF BrutsaertDL SegersVF De KeulenaerGW The continuous heart failure spectrum: moving beyond an ejection fraction classification Eur Heart J. 2019 40 2155 63 10.1093/eurheartj/ehz158796312930957868 Search in Google Scholar

4 Ueda M, Horibata Y, Shono M, Misumi Y, Oshima T, Su Y, Tasaki M, Shinriki S, Kawahara S, Jono H, Obayashi K, Ogawa H, Ando Y. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol 2011; 24:1533–44. UedaM HoribataY ShonoM MisumiY OshimaT SuY TasakiM ShinrikiS KawaharaS JonoH ObayashiK OgawaH AndoY Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study Mod Pathol 2011 24 1533 44 10.1038/modpathol.2011.11721822203 Search in Google Scholar

5 Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, Haro Del-Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015; 36:2585–94. Gonzalez-LopezE Gallego-DelgadoM Guzzo-MerelloG Haro Del-MoralFJ Cobo-MarcosM RoblesC BornsteinB SalasC Lara-PezziE Alonso-PulponL Garcia-PaviaP Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction Eur Heart J. 2015 36 2585 94 10.1093/eurheartj/ehv33826224076 Search in Google Scholar

6 Scully PR, Treibel TA, Fontana M, Lloyd G, Mullen M, Pugliese F, Hartman N, Hawkins PN, Menezes LJ, Moon JC. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol. 2018; 71:463–4. ScullyPR TreibelTA FontanaM LloydG MullenM PuglieseF HartmanN HawkinsPN MenezesLJ MoonJC Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement J Am Coll Cardiol. 2018 71 463 4 10.1016/j.jacc.2017.11.037578029729389364 Search in Google Scholar

7 Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, Roberts N, Hutt DF, Rowczenio DM, Whelan CJ, Ashworth MA, Gillmore JD, Hawkins PN, Moon JC. Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016;9:e005066 TreibelTA FontanaM GilbertsonJA CastellettiS WhiteSK ScullyPR RobertsN HuttDF RowczenioDM WhelanCJ AshworthMA GillmoreJD HawkinsPN MoonJC Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and prognosis in patients undergoing surgical aortic valve replacement Circ Cardiovasc Imaging 2016 9 e005066 10.1161/CIRCIMAGING.116.00506627511979 Search in Google Scholar

8 Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021; 42:1554–68. Garcia-PaviaP RapezziC AdlerY AradM BassoC BrucatoA BurazorI CaforioALP DamyT ErikssonU FontanaM GillmoreJD Gonzalez-LopezE GroganM HeymansS ImazioM KindermannI KristenAV MaurerMS MerliniG PantazisA PankuweitS RigopoulosAG LinhartA Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Eur J Heart Fail. 2021 42 1554 68 10.1093/eurheartj/ehab072806005633825853 Search in Google Scholar

9 Bennani Smires Y, Victor G, Ribes D, Berry M, Cognet T, Mejean S, Huart A, Roussel M, Petermann A, Roncalli J, Carrie D, Rousseau H, Berry I, Chauveau D, Galinier M, Lairez O. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int J Card Imaging. 2016; 32:1403–13. Bennani SmiresY VictorG RibesD BerryM CognetT MejeanS HuartA RousselM PetermannA RoncalliJ CarrieD RousseauH BerryI ChauveauD GalinierM LairezO Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy Int J Card Imaging. 2016 32 1403 13 10.1007/s10554-016-0915-z27240600 Search in Google Scholar

10 Tuzovic M, Yang EH, Baas AS, Depasquale EC, Deng MC, Cruz D, Vorobiof G. Cardiac amyloidosis: diagnosis and treatment strategies. Curr Oncol Rep 2017; 19:46. TuzovicM YangEH BaasAS DepasqualeEC DengMC CruzD VorobiofG Cardiac amyloidosis: diagnosis and treatment strategies Curr Oncol Rep 2017 19 46 10.1007/s11912-017-0607-428528458 Search in Google Scholar

11 Mohammed SF, Mirzovev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014; 2:113–22. MohammedSF MirzovevSA EdwardsWD DoganA GroganDR DunlaySM RogerVL GertzMA DispenzieriA ZeldenrustSR RedfieldMM Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction JACC Heart Fail 2014 2 113 22 10.1016/j.jchf.2013.11.004398453924720917 Search in Google Scholar

12 Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol 2015; 12:91–102. GertzMA DispenzieriA SherT Pathophysiology and treatment of cardiac amyloidosis Nat Rev Cardiol 2015 12 91 102 10.1038/nrcardio.2014.16525311231 Search in Google Scholar

13 Gertz MA. Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment. Am J Hematol 2018; 93:1169–80. GertzMA Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment Am J Hematol 2018 93 1169 80 10.1002/ajh.2514930040145 Search in Google Scholar

14 Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015; 20:163–78. CastañoA DrachmanBM JudgeD MaurerMS Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs Heart Fail Rev. 2015 20 163 78 10.1007/s10741-014-9462-7436130225408161 Search in Google Scholar

15 Patel KS, Hawkins PN. Cardiac amyloidosis: where are we today? J Intern Med. 2015; 278:126–44. PatelKS HawkinsPN Cardiac amyloidosis: where are we today? J Intern Med. 2015 278 126 44 10.1111/joim.1238326077367 Search in Google Scholar

16 Sandra Ihne, Caroline Morbach, Laura Obici, Giovanni Palladini, Stefan Störk. Amyloidosis in Heart Failure. Curr Heart Fail Rep. 2019; 16:285–303. IhneSandra MorbachCaroline ObiciLaura PalladiniGiovanni StörkStefan Amyloidosis in Heart Failure Curr Heart Fail Rep. 2019 16 285 303 10.1007/s11897-019-00446-x31782077 Search in Google Scholar

17 Benson MD, Dasgupta MR. Amyloid cardiomyopathy. J Am Coll Cardiol 2016; 68:25–8. BensonMD DasguptaMR Amyloid cardiomyopathy J Am Coll Cardiol 2016 68 25 8 10.1016/j.jacc.2016.05.00927364046 Search in Google Scholar

18 Gertz MA. Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment. Am J Hematol 2018; 93:1169–80. GertzMA Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment Am J Hematol 2018 93 1169 80 10.1002/ajh.25149 Search in Google Scholar

19 Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy A systematic review. JAMA 2020; 324:79–89. GertzMA DispenzieriA Systemic amyloidosis recognition, prognosis, and therapy A systematic review JAMA 2020 324 79 89 10.1001/jama.2020.549332633805 Search in Google Scholar

20 Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood 2016; 128:159–68. PalladiniG MerliniG What is new in diagnosis and management of light chain amyloidosis? Blood 2016 128 159 68 10.1182/blood-2016-01-62979027053535 Search in Google Scholar

21 Kyle RA, Larson DR, Kurtin PJ, Kumar S, Cerhan JR, Therneau TM, Rajkumar SV, Vachon CM, Dispenzieri A. Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc 2019; 94:465–71. KyleRA LarsonDR KurtinPJ KumarS CerhanJR TherneauTM RajkumarSV VachonCM DispenzieriA Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015 Mayo Clin Proc 2019 94 465 71 10.1016/j.mayocp.2018.08.041640126230713046 Search in Google Scholar

22 Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, Sipe JD, Westermark P. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2018; 25:215–9. BensonMD BuxbaumJN EisenbergDS MerliniG SaraivaMJM SekijimaY SipeJD WestermarkP Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee Amyloid 2018 25 215 9 10.1080/13506129.2018.154982530614283 Search in Google Scholar

23 Arciello A, Piccoli R, Monti DM. Apolipoprotein A-I: the dual face of a protein. FEBS Lett. 2016; 590:4171–9. ArcielloA PiccoliR MontiDM Apolipoprotein A-I: the dual face of a protein FEBS Lett. 2016 590 4171 9 10.1002/1873-3468.1246827790714 Search in Google Scholar

24 Quarta CC, Gonzalez-Lopez E, Gilbertson JA, Botcher N, Rowczenio D, Petrie A, Rezk T, Youngstein T, Mahmood S, Sachchithanantham S, Lachmann HJ, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Gillmore JD. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J. 2017; 38:1905–8. QuartaCC Gonzalez-LopezE GilbertsonJA BotcherN RowczenioD PetrieA RezkT YoungsteinT MahmoodS SachchithananthamS LachmannHJ FontanaM WhelanCJ WechalekarAD HawkinsPN GillmoreJD Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis Eur Heart J. 2017 38 1905 8 10.1093/eurheartj/ehx047583722928605421 Search in Google Scholar

25 Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001; 98:714–20. ComenzoRL ZhangY MartinezC OsmanK HerreraGA The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden Blood. 2001 98 714 20 10.1182/blood.V98.3.71411468171 Search in Google Scholar

26 Perfetti V, Casarini S, Palladini G, Vignarelli MC, Klersy C, Diegoli M, Ascari E, Merlini G. Analysis of V (lambda)-J (lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood. 2002; 100:948–53. PerfettiV CasariniS PalladiniG VignarelliMC KlersyC DiegoliM AscariE MerliniG Analysis of V (lambda)-J (lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment Blood. 2002 100 948 53 10.1182/blood-2002-01-011412130507 Search in Google Scholar

27 Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain associated amyloidosis (AL). Blood. 2003; 101:3801–8. AbrahamRS GeyerSM Price-TroskaTL AllmerC KyleRA GertzMA FonsecaR Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain associated amyloidosis (AL) Blood. 2003 101 3801 8 10.1182/blood-2002-09-270712515719 Search in Google Scholar

28 Perfetti V, Palladini G, Casarini S, Navazza V, Rognoni P, Obici L, Invernizzi R, Perlini S, Klersy C, Merlini G. The repertoire of lambda light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood. 2012; 119:144–50. PerfettiV PalladiniG CasariniS NavazzaV RognoniP ObiciL InvernizziR PerliniS KlersyC MerliniG The repertoire of lambda light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44 Blood. 2012 119 144 50 10.1182/blood-2011-05-35578422067386 Search in Google Scholar

29 Kourelis TV, Dasari S, Theis JD, Ramirez-Alvarado M, Kurtin PJ, Gertz MA, Zeldenrust SR, Zenka RM, Dogan A, Dispenzieri A. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood. 2017; 129:299–306. KourelisTV DasariS TheisJD Ramirez-AlvaradoM KurtinPJ GertzMA ZeldenrustSR ZenkaRM DoganA DispenzieriA Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry Blood. 2017 129 299 306 10.1182/blood-2016-10-74399727856462 Search in Google Scholar

30 Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell AR, Melzi D’Eril GV, Fogari R, Moratti R, Merlini G. Circulating amyloidogenic free light chains and serum Nterminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006; 107:3854–8. PalladiniG LavatelliF RussoP PerliniS PerfettiV BosoniT ObiciL BradwellAR Melzi D’ErilGV FogariR MorattiR MerliniG Circulating amyloidogenic free light chains and serum Nterminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL Blood. 2006 107 3854 8 10.1182/blood-2005-11-438516434487 Search in Google Scholar

31 Milani P, Merlini G, Palladini G. Light chain amyloidosis. Mediterr J Hematol Infect Dis. 2018;10: e2018022. MilaniP MerliniG PalladiniG Light chain amyloidosis Mediterr J Hematol Infect Dis 2018 10 e2018022 10.4084/mjhid.2018.022 Search in Google Scholar

32 Lin HM, Gao X, Cooke CE, Berg D, Labotka R, Faller DV, Seal B, Hari P. Disease burden of systemic light-chain amyloidosis: a systematic literature review. Curr Med Res Opin. 2017; 33:1017–31. LinHM GaoX CookeCE BergD LabotkaR FallerDV SealB HariP Disease burden of systemic light-chain amyloidosis: a systematic literature review Curr Med Res Opin. 2017 33 1017 31 10.1080/03007995.2017.129793028277869 Search in Google Scholar

33 Merlini G, Dispenzieri A, Sanchorawala V, Schonland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4:38. MerliniG DispenzieriA SanchorawalaV SchonlandSO PalladiniG HawkinsPN GertzMA Systemic immunoglobulin light chain amyloidosis Nat Rev Dis Primers 2018 4 38 10.1038/s41572-018-0034-330361521 Search in Google Scholar

34 Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, Massie R, Narayan J, Swiggum E, Venner CP, Ducharme A, Galant NJ, Hahn C, Howlett JG, Mielniczuk L, Parent MC, Reece D, Royal V, Toma M, Virani SA, Zieroth S. Canadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis. Can J Cardiol. 2020;36:322–34. FineNM DavisMK AndersonK DelgadoDH GiraldeauG KitchluA MassieR NarayanJ SwiggumE VennerCP DucharmeA GalantNJ HahnC HowlettJG MielniczukL ParentMC ReeceD RoyalV TomaM ViraniSA ZierothS Canadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis Can J Cardiol 2020 36 322 34 10.1016/j.cjca.2019.12.03432145862 Search in Google Scholar

35 Khanna S, Wen I, Bhat A, Chen HHL, Gan GCH, Pathan F, Tan TC. The role of multi-modality imaging in the diagnosis of cardiac amyloidosis: a focused update. Front Cardiovasc Med. 2020;7:212. KhannaS WenI BhatA ChenHHL GanGCH PathanF TanTC The role of multi-modality imaging in the diagnosis of cardiac amyloidosis: a focused update Front Cardiovasc Med 2020 7 212 10.3389/fcvm.2020.590557766168933195479 Search in Google Scholar

36 González-López E, López-Sainz Á, Garcia-Pavia P. Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hope. Rev Esp Cardiol. 2017; 70:991–1004. González-LópezE López-SainzÁ Garcia-PaviaP Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hope Rev Esp Cardiol. 2017 70 991 1004 10.1016/j.rec.2017.05.03628870641 Search in Google Scholar

37 Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019; 73:2872–91. RubergFL GroganM HannaM KellyJW MaurerMS Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review J Am Coll Cardiol. 2019 73 2872 91 10.1016/j.jacc.2019.04.003672418331171094 Search in Google Scholar

38 Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011; 97:75–84. DubreySW HawkinsPN FalkRH Amyloid diseases of the heart: assessment, diagnosis, and referral Heart 2011 97 75 84 10.1136/hrt.2009.19040521148582 Search in Google Scholar

39 Nakagawa M, Sekijima Y, Yazaki M, Tojo K, Yoshinaga T, Doden T, Koyama J, Yanagisawa S, Ikeda SI. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016; 23:58–63. NakagawaM SekijimaY YazakiM TojoK YoshinagaT DodenT KoyamaJ YanagisawaS IkedaSI Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis Amyloid. 2016 23 58 63 10.3109/13506129.2015.113579226852880 Search in Google Scholar

40 Westermark P, Westermark GT, Suhr OB, Berg S. Transthyretin derived amyloidosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci. 2014; 119:223–8. WestermarkP WestermarkGT SuhrOB BergS Transthyretin derived amyloidosis: probably a common cause of lumbar spinal stenosis Ups J Med Sci. 2014 119 223 8 10.3109/03009734.2014.895786411676124620715 Search in Google Scholar

41 Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2020; 268:2109–22. AdamsD AndoY BeirãoJM CoelhoT GertzMA GillmoreJD HawkinsPN LousadaI SuhrOB MerliniG Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy J Neurol. 2020 268 2109 22 10.1007/s00415-019-09688-0817991231907599 Search in Google Scholar

42 Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I) cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med. 2017; 19:733–42. BuxbaumJN RubergFL Transthyretin V122I (pV142I) cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans Genet Med. 2017 19 733 42 10.1038/gim.2016.200550949828102864 Search in Google Scholar

43 Agha AM, Parwani P, Guha A, Durand JB, Iliescu CA, Hassan S, Palaskas NL, Gladish G, Kim PY, Lopez-Mattei J. Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis. Open Heart. 2018;5:e000881–e000881 AghaAM ParwaniP GuhaA DurandJB IliescuCA HassanS PalaskasNL GladishG KimPY Lopez-MatteiJ Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis Open Heart 2018 5 e000881 e000881 10.1136/openhrt-2018-000881617326730305910 Search in Google Scholar

44 Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure. Arch Intern Med 2005; 165:1425–9. NgB ConnorsLH DavidoffR SkinnerM FalkRH Senile systemic amyloidosis presenting with heart failure Arch Intern Med 2005 165 1425 9 10.1001/archinte.165.12.142515983293 Search in Google Scholar

45 Perfetto F, Bergesio F, Emdin M, Capelli F. Troponins in cardiac amyloidosis: multipurpose markers. Nat Rev Cardiol. 2014; 11:179. PerfettoF BergesioF EmdinM CapelliF Troponins in cardiac amyloidosis: multipurpose markers Nat Rev Cardiol 2014 11 179 10.1038/nrcardio.2013.129-c124469674 Search in Google Scholar

46 Neben-Wittich MA, Wittich CM, Mueller PS, Larson DR, Gertz MA, Edwards WD. Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med. 2005;118:1287. Neben-WittichMA WittichCM MuellerPS LarsonDR GertzMA EdwardsWD Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis Am J Med 2005 118 1287 10.1016/j.amjmed.2005.06.01716271914 Search in Google Scholar

47 Dorbala S, Vangala D, Bruyere J, Quarta C, Kruger J, Padera R, Foster C, Hanley M, Di Carli MF, Falk R. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2:358–67. DorbalaS VangalaD BruyereJ QuartaC KrugerJ PaderaR FosterC HanleyM Di CarliMF FalkR Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis JACC Heart Fail 2014 2 358 67 10.1016/j.jchf.2014.03.009412714525023822 Search in Google Scholar

48 Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017; 135:1357–77. MaurerMS ElliottP ComenzoR SemigranM RapezziC Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis Circulation 2017 135 1357 77 10.1161/CIRCULATIONAHA.116.024438539241628373528 Search in Google Scholar

49 Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, Grogan M, Kristen AV, Lousada I, Nativi-Nicolau J, Quarta CC, Rapezzi C, Ruberg FL, Witteles R, Merlini G. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12: e006075. MaurerMS BokhariS DamyT DorbalaS DrachmanBM FontanaM GroganM KristenAV LousadaI Nativi-NicolauJ QuartaCC RapezziC RubergFL WittelesR MerliniG Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis Circ Heart Fail 2019 12 e006075 10.1161/CIRCHEARTFAILURE.119.006075673665031480867 Search in Google Scholar

50 Zhongwei Cheng, Kongbo Zhu, Zhuang Tian, Dachun Zhao., Quancai Cui M.D. Quan Fang M.D. The findings of electrocardiography in patients with cardiac amyloidosis. Ann Noninvasive Electrocardiol. 2013; 18:157–62. ChengZhongwei ZhuKongbo TianZhuang ZhaoDachun CuiQuancaiM.D. FangQuanM.D. The findings of electrocardiography in patients with cardiac amyloidosis. Ann Noninvasive Electrocardiol. 2013 18 157 62 10.1111/anec.12018693243223530486 Search in Google Scholar

51 Dungu JN, Sattianayagam PT, Whelan CJ, Gibbs SD, Pinney JH, Banypersad SM, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Hawkins PN, Anderson LJ. The electrocardio graphic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in afro-caribbean patients. Am Heart J 2012; 164:72–9. DunguJN SattianayagamPT WhelanCJ GibbsSD PinneyJH BanypersadSM RowczenioD GilbertsonJA LachmannHJ WechalekarA GillmoreJD HawkinsPN AndersonLJ The electrocardio graphic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in afro-caribbean patients Am Heart J 2012 164 72 9 10.1016/j.ahj.2012.04.01322795285 Search in Google Scholar

52 Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005; 95:535–7. MurtaghB HammillSC GertzMA KyleRA TajikAJ GroganM Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement Am J Cardiol 2005 95 535 7 10.1016/j.amjcard.2004.10.02815695149 Search in Google Scholar

53 Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, Hare JM, Baughman KL, Kasper EK. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 2004; 43:410–5. RahmanJE HelouEF Gelzer-BellR ThompsonRE KuoC RodriguezER HareJM BaughmanKL KasperEK Noninvasive diagnosis of biopsy-proven cardiac amyloidosis J Am Coll Cardiol 2004 43 410 5 10.1016/j.jacc.2003.08.04315013123 Search in Google Scholar

54 Austin BA, Duffy B, Tan C, Rodriguez ER, Starling RC, Desai MY. Comparison of functional status, electrocardiographic, and echo car diographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosis. Am J Cardiol 2009; 103:1429–33. AustinBA DuffyB TanC RodriguezER StarlingRC DesaiMY Comparison of functional status, electrocardiographic, and echo car diographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosis Am J Cardiol 2009 103 1429 33 10.1016/j.amjcard.2009.01.36119427441 Search in Google Scholar

55 Mussinelli R, Salinaro F, Alogna A, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G, Perlini S. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol. 2013; 18:271–80. MussinelliR SalinaroF AlognaA BoldriniM RaimondiA MuscaF PalladiniG MerliniG PerliniS Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis Ann Noninvasive Electrocardiol. 2013 18 271 80 10.1111/anec.12036693219223714086 Search in Google Scholar

56 Namdar M, Steffel J, Jetzer S, Schmied C, Hurlimann D, Camici GG, Bayrak F, Ricciardi D, Rao JY, de Asmundis C, Chiercia GB, Sarkozy A, Luscher TF, Jenni R, Duru F, Brugada P. Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease. Am J Cardiol 2012; 109:587–93. NamdarM SteffelJ JetzerS SchmiedC HurlimannD CamiciGG BayrakF RicciardiD RaoJY de AsmundisC ChierciaGB SarkozyA LuscherTF JenniR DuruF BrugadaP Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease Am J Cardiol 2012 109 587 93 10.1016/j.amjcard.2011.09.05222105784 Search in Google Scholar

57 Perlini S, Salinaro F, Cappelli F, Perfetto F, Bergesio F, Alogna A, Mussinelli R, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G. Prognostic value of fragmented QRS in cardiac AL amyloidosis. Int J Cardiol 2013; 167:2156–61. PerliniS SalinaroF CappelliF PerfettoF BergesioF AlognaA MussinelliR BoldriniM RaimondiA MuscaF PalladiniG MerliniG Prognostic value of fragmented QRS in cardiac AL amyloidosis Int J Cardiol 2013 167 2156 61 10.1016/j.ijcard.2012.05.09722748496 Search in Google Scholar

58 Granstam SO, Rosengren S, Vedin O, Kero T, Sorensen J, Carlson K, Flachsckampf FA, Wikstrom G. Evaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catheterization. Amyloid 2013; 20:27–33. GranstamSO RosengrenS VedinO KeroT SorensenJ CarlsonK FlachsckampfFA WikstromG Evaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catheterization Amyloid 2013 20 27 33 10.3109/13506129.2012.76196723339421 Search in Google Scholar

59 Boldrini M, Salinaro F, Mussinelli R, Raimondi A, Alogna A, Musca F, Palladini G, Merlini G, Perlini S. Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac al amyloidosis. Ann Noninvasive Electrocardiol 2013; 18:327–35. BoldriniM SalinaroF MussinelliR RaimondiA AlognaA MuscaF PalladiniG MerliniG PerliniS Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac al amyloidosis Ann Noninvasive Electrocardiol 2013 18 327 35 10.1111/anec.12032693203523879272 Search in Google Scholar

60 Reyners AK, Hazenberg BP, Reitsma WD, Smit AJ. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J 2002; 23:157–61. ReynersAK HazenbergBP ReitsmaWD SmitAJ Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis Eur Heart J 2002 23 157 61 10.1053/euhj.2001.297211785998 Search in Google Scholar

61 Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 2014; 7:552–62. FalkRH QuartaCC DorbalaS How to image cardiac amyloidosis Circ Cardiovasc Imaging. 2014 7 552 62 10.1161/CIRCIMAGING.113.001396411830824847009 Search in Google Scholar

62 Bradshaw SH, Veinot JP. Cardiac amyloidosis. Curr Opin Cardiol 2012; 27:143–7. BradshawSH VeinotJP Cardiac amyloidosis Curr Opin Cardiol 2012 27 143 7 10.1097/HCO.0b013e32834fdc7e22314298 Search in Google Scholar

63 Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lackmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AWJM, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazemberg BP, Rapezzi C, Hawkins PN. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133:2404–12. GillmoreJD MaurerMS FalkRH MerliniG DamyT DispenzieriA WechalekarAD BerkJL QuartaCC GroganM LackmannHJ BokhariS CastanoA DorbalaS JohnsonGB GlaudemansAWJM RezkT FontanaM PalladiniG MilaniP GuidalottiPL FlatmanK LaneT VonbergFW WhelanCJ MoonJC RubergFL MillerEJ HuttDF HazembergBP RapezziC HawkinsPN Nonbiopsy diagnosis of cardiac transthyretin amyloidosis Circulation 2016 133 2404 12 10.1161/CIRCULATIONAHA.116.02161227143678 Search in Google Scholar

64 Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016; 68:1014–20. GroganM ScottCG KyleRA ZeldenrustSR GertzMA LinG KlarichKW MillerWL MaleszewskiJJ DispenzieriA Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system J Am Coll Cardiol. 2016 68 1014 20 10.1016/j.jacc.2016.06.03327585505 Search in Google Scholar

65 Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018; 39:2799–806. GillmoreJD DamyT FontanaM HutchinsonM LachmannHJ Martinez-NaharroA QuartaCC RezkT WhelanCJ Gonzalez-LopezE LaneT GilbertsonJA RowczenioD PetrieA HawkinsPN A new staging system for cardiac transthyretin amyloidosis Eur Heart J. 2018 39 2799 806 10.1093/eurheartj/ehx58929048471 Search in Google Scholar

67 Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, Marwick TH, Thomas JD. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98:1442–8. PhelanD CollierP ThavendiranathanP PopovicZB HannaM PlanaJC MarwickTH ThomasJD Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis Heart 2012 98 1442 8 10.1136/heartjnl-2012-30235322865865 Search in Google Scholar

68 Pagourelias ED, Duchenne J, Mirea O, Vovas G, Van Cleemput J, Delforge M, Kuznetsova T, Boagert J, Voigt JU. The relation of ejection fraction and global longitudinal strain in amyloidosis: implications for differential diagnosis. JACC Cardiovasc Imaging. 2016; 9:1358–9. PagoureliasED DuchenneJ MireaO VovasG Van CleemputJ DelforgeM KuznetsovaT BoagertJ VoigtJU The relation of ejection fraction and global longitudinal strain in amyloidosis: implications for differential diagnosis JACC Cardiovasc Imaging. 2016 9 1358 9 10.1016/j.jcmg.2015.11.01326897665 Search in Google Scholar

69 Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J, Kuznetsova T, Voigt JU. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging. 2017;10: e005588. PagoureliasED MireaO DuchenneJ Van CleemputJ DelforgeM BogaertJ KuznetsovaT VoigtJU Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters Circ Cardiovasc Imaging 2017 10 e005588 10.1161/CIRCIMAGING.116.00558828298286 Search in Google Scholar

70 Ono K, Ishimaru G, Hayashi M, Bae Y, Ito T, Izumo T, Murata K. The imaging diagnosis of less advanced cases of cardiac amyloidosis: the relative apical sparing pattern. Intern Med. 2017; 56:315–9. OnoK IshimaruG HayashiM BaeY ItoT IzumoT MurataK The imaging diagnosis of less advanced cases of cardiac amyloidosis: the relative apical sparing pattern Intern Med. 2017 56 315 9 10.2169/internalmedicine.56.7610534845628154276 Search in Google Scholar

71 Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, Radu C, Guendouz S, Couetil JP, Benhaiem N, Hittinger L, Dubois-Rande JL, Plante-Bordeneuve V, Mohty D, Feux JF, Damy T. Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9:126–38. TernacleJ BodezD GuellichA AudureauE RappeneauS LimP RaduC GuendouzS CouetilJP BenhaiemN HittingerL Dubois-RandeJL Plante-BordeneuveV MohtyD FeuxJF DamyT Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis JACC Cardiovasc Imaging 2016 9 126 38 10.1016/j.jcmg.2015.05.01426777222 Search in Google Scholar

72 Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Kotecha T, Francis R, Rezk T, Quarta CC, Whelan CJ, Lachmann HL, Wechalekar AD, Gillmore JD, Moon JC, Hawkins PN, Fontana M. Cardiac sructural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC: Cardiovascular Imaging. 2019;12:823–33. KnightDS ZumboG BarcellaW SteedenJA MuthuranguV Martinez-NaharroA TreibelTA Abdel-GadirA BulluckH KotechaT FrancisR RezkT QuartaCC WhelanCJ LachmannHL WechalekarAD GillmoreJD MoonJC HawkinsPN FontanaM Cardiac sructural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles JACC: Cardiovascular Imaging 2019 12 823 33 Search in Google Scholar

73 Pun SC, Landau HJ, Riedel ER, Jordan J, Yu AF, Hassoun H, Chen CL, Steingart RM, Liu JE. Prognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantation. J Am Soc Echocardiogr. 2018;31:64–70. PunSC LandauHJ RiedelER JordanJ YuAF HassounH ChenCL SteingartRM LiuJE Prognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantation J Am Soc Echocardiogr 2018 31 64 70 10.1016/j.echo.2017.08.017 Search in Google Scholar

74 Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL, American Heart Association heart failure and transplantation committee of the council on clinical cardiology. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142:7–22. KittlesonMM MaurerMS AmbardekarAV Bullock-PalmerRP ChangPP EisenHJ NairAP Nativi-NicolauJ RubergFL American Heart Association heart failure and transplantation committee of the council on clinical cardiology. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association Circulation 2020 142 7 22 10.1161/CIR.0000000000000792 Search in Google Scholar

75 Jurcut R, Onciul S, Adam R, Stan C, Coriu D, Rapezzi C, Popescu BA. Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. Eur Heart J Cardiovasc Imaging, 2020;21:833–44. JurcutR OnciulS AdamR StanC CoriuD RapezziC PopescuBA Multimodality imaging in cardiac amyloidosis: a primer for cardiologists Eur Heart J Cardiovasc Imaging 2020 21 833 44 10.1093/ehjci/jeaa063 Search in Google Scholar

76 Roger-Rollé A, Cariou E, Rguez K, Fournier P, Lavie-Badie Y, Blanchard V, Roncalli J, Galinier M, Carrie D, Lairez O, Toulouse Amyloidosis Research Network collaborators. Can myocardial work indices contribute to the exploration of patients with cardiac amyloidosis? Open Heart 2020;7:e001346. Roger-RolléA CariouE RguezK FournierP Lavie-BadieY BlanchardV RoncalliJ GalinierM CarrieD LairezO Toulouse Amyloidosis Research Network collaborators Can myocardial work indices contribute to the exploration of patients with cardiac amyloidosis? Open Heart 2020 7 e001346 10.1136/openhrt-2020-001346 Search in Google Scholar

77 Sakamoto M, Funada A, Amaki M, Ohara T, Hasegawa T, Sugano Y, Kanzaky H, Kitakaze M, Anzai T. More impaired diastolic function of light chain amyloidosis contributes to poor prognosis compared with transthyretin amyloidosis: result from longitudinal study of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2015;65: A935. SakamotoM FunadaA AmakiM OharaT HasegawaT SuganoY KanzakyH KitakazeM AnzaiT More impaired diastolic function of light chain amyloidosis contributes to poor prognosis compared with transthyretin amyloidosis: result from longitudinal study of biopsy-proven cardiac amyloidosis J Am Coll Cardiol 2015 65 A935 10.1016/S0735-1097(15)60935-4 Search in Google Scholar

78 Stricagnoli M, Cameli M, Incampo E, Lunghetti S, Mondillo S. Speckle tracking echocardiography in cardiac amyloidosis. Heart Fail Rev. 2019; 24:701–7. StricagnoliM CameliM IncampoE LunghettiS MondilloS Speckle tracking echocardiography in cardiac amyloidosis Heart Fail Rev. 2019 24 701 7 10.1007/s10741-019-09796-z30989593 Search in Google Scholar

79 Clemmensen TS, Eiskjær H, Mikkelsen F, Granstam SO, Flachskampf FA, Sørensen J, Poulsen SH. Left ventricular pressure-strain-derived myocardial work at rest and during exercise in patients with cardiac amyloidosis. J Am Soc Echocardiogr. 2020; 33:573–82. ClemmensenTS EiskjærH MikkelsenF GranstamSO FlachskampfFA SørensenJ PoulsenSH Left ventricular pressure-strain-derived myocardial work at rest and during exercise in patients with cardiac amyloidosis J Am Soc Echocardiogr. 2020 33 573 82 10.1016/j.echo.2019.11.01832061410 Search in Google Scholar

80 Dungu JN, Valencia O, Pinney JH, Gibbs SDJ, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7:133–42. DunguJN ValenciaO PinneyJH GibbsSDJ RowczenioD GilbertsonJA LachmannHJ WechalekarA GillmoreJD WhelanCJ HawkinsPN AndersonLJ CMR-based differentiation of AL and ATTR cardiac amyloidosis JACC Cardiovasc Imaging 2014 7 133 42 10.1016/j.jcmg.2013.08.01524412186 Search in Google Scholar

81 Oda S, Utsunomiya D, Nakaura T, Takashio S, Izumiya Y, Tsujita K, Ueda M, Yamashita T, Ando Y, Kawano Y, Okuno Y, Hata H, Yamashita Y. Role of noninvasive diagnostic imaging in cardiac amyloidosis: a review. Cardiovasc Imaging Asia. 2018; 2:97–106. OdaS UtsunomiyaD NakauraT TakashioS IzumiyaY TsujitaK UedaM YamashitaT AndoY KawanoY OkunoY HataH YamashitaY Role of noninvasive diagnostic imaging in cardiac amyloidosis: a review Cardiovasc Imaging Asia. 2018 2 97 106 10.22468/cvia.2018.00059 Search in Google Scholar

82 Fontana M, Chung R, Hawkins PN, Moon JC. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev 2015; 20:133–44. FontanaM ChungR HawkinsPN MoonJC Cardiovascular magnetic resonance for amyloidosis Heart Fail Rev 2015 20 133 44 10.1007/s10741-014-9470-725549885 Search in Google Scholar

83 Wan K, Sun J, Han Y, Liu H, Yang D, Li W, Wang J, Cheng W, Zhang Q, Zeng Z, Chen Y. Increased prognostic value of query amyloid late enhancement score in light-chain cardiac amyloidosis. Circ J. 2018;82:739–46. WanK SunJ HanY LiuH YangD LiW WangJ ChengW ZhangQ ZengZ ChenY Increased prognostic value of query amyloid late enhancement score in light-chain cardiac amyloidosis Circ J 2018 82 739 46 10.1253/circj.CJ-17-046429093431 Search in Google Scholar

84 Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013; 6:488–97. KaramitsosTD PiechnikSK BanypersadSM FontanaM NtusiNB FerreiraVM WhelanCJ MyersonSG RobsonMD HawkinsPN NeubauerS MoonJC Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis JACC Cardiovasc Imaging. 2013 6 488 97 10.1016/j.jcmg.2012.11.01323498672 Search in Google Scholar

85 Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, Piechnik SK, Whelan CJ, Herrey AS, Gillmore JD, Lachmann HJ, Wechalekar AD, Hawkins PN, Moon JC. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015; 21:244–51. BanypersadSM FontanaM MaestriniV SadoDM CapturG PetrieA PiechnikSK WhelanCJ HerreyAS GillmoreJD LachmannHJ WechalekarAD HawkinsPN MoonJC T1 mapping and survival in systemic light-chain amyloidosis Eur Heart J. 2015 21 244 51 10.1093/eurheartj/ehu444430159825411195 Search in Google Scholar

86 Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis using ^99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005; 46:1076–84. PeruginiE GuidalottiPL SalviF CookeRMT PettinatoC RivaL LeoneO FarsadM CilibertiP Bacchi-ReggianiL FallaniF BranziA RapezziC Noninvasive etiologic diagnosis of cardiac amyloidosis using ^99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy J Am Coll Cardiol. 2005 46 1076 84 10.1016/j.jacc.2005.05.07316168294 Search in Google Scholar

87 Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SDJ, Venner CP, Wassef N, McCarthy CA, Gillbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2: e000098. PinneyJH WhelanCJ PetrieA DunguJ BanypersadSM SattianayagamP WechalekarA GibbsSDJ VennerCP WassefN McCarthyCA GillbertsonJA RowczenioD HawkinsPN GillmoreJD LachmannHJ Senile systemic amyloidosis: clinical features at presentation and outcome J Am Heart Assoc 2013 2 e000098 10.1161/JAHA.113.000098364725923608605 Search in Google Scholar

88 Kim D, Choi J-O, Kim K, Kim SJ, Jeon E-S. Untangling amyloidosis: recent advances in cardiac amyloidosis. Int J Heart Fail. 2020; 2:231–9. KimD ChoiJ-O KimK KimSJ JeonE-S Untangling amyloidosis: recent advances in cardiac amyloidosis Int J Heart Fail. 2020 2 231 9 10.36628/ijhf.2020.0016 Search in Google Scholar

89 van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006; 54:2015–21. van GamerenII HazenbergBP BijzetJ van RijswijkMH Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice Arthritis Rheum. 2006 54 2015 21 10.1002/art.2190216732553 Search in Google Scholar

90 Swan N, Skinner M, O’Hara CJ. Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases. Am J Clin Pathol. 2003; 120:610–6. SwanN SkinnerM O’HaraCJ Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases Am J Clin Pathol. 2003 120 610 6 10.1309/PFUGHBX0TY20E08U Search in Google Scholar

91 Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002; 346:1786–91. LachmannHJ BoothDR BoothSE BybeeA GilbertsonJA GillmoreJD PepysMB HawkinsPN Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis N Engl J Med. 2002 346 1786 91 10.1056/NEJMoa01335412050338 Search in Google Scholar

92 Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009; 114:4957–9. VranaJA GamezJD MaddenBJ TheisJD BergenHR3rd DoganA Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens Blood. 2009 114 4957 9 10.1182/blood-2009-07-23072219797517 Search in Google Scholar

93 Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulus MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121:3420–7. WechalekarAD SchonlandSO KastritisE GillmoreJD DimopoulusMA LaneT FoliA FoardD MilaniP RanniganL HegenbartU HawkinsPN MerliniG PalladiniG A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis Blood 2013 121 3420 7 10.1182/blood-2012-12-47306623479568 Search in Google Scholar

94 Dispenzieri A, Gertz MA, Kyle Lacy MQ, Burrit MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CGA, Jaffe AS. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004; 104:1881–7. DispenzieriA GertzMA Kyle LacyMQ BurritMF TherneauTM McConnellJP LitzowMR GastineauDA TefferiA InwardsDJ MicallefIN AnsellSM PorrataLF ElliottMA HoganWJ RajkumarSV FonsecaR GreippPR WitzigTE LustJA ZeldenrustSR SnowDS HaymanSR McGregorCGA JaffeAS Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Blood. 2004 104 1881 7 10.1182/blood-2004-01-039015044258 Search in Google Scholar

95 Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli, Obici L, Perlini S, Moratti R, Merlini G. Best use of cardiac biomarkers in patients with AL Amyloidosis and renal failure. Am J Hematol 2012; 87:465–71. PalladiniG FoliA MilaniP RussoP AlbertiniR Lavatelli ObiciL PerliniS MorattiR MerliniG Best use of cardiac biomarkers in patients with AL Amyloidosis and renal failure Am J Hematol 2012 87 465 71 10.1002/ajh.2314122389105 Search in Google Scholar

96 Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia 2012; 26:2317–25. ComenzoRL ReeceD PalladiniG SeldinD SanchorawalaV LandauH FalkR WellsK SolomonA WechalekarA ZonderJ DispenzieriA GertzM StreicherH SkinnerM KyleRA MerliniG Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis Leukemia 2012 26 2317 25 10.1038/leu.2012.10022475872 Search in Google Scholar

97 Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schonland S, Hegebart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in Immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes. J Clin Oncol 2012; 30:4541–9. PalladiniG DispenzieriA GertzMA KumarS WechalekarA HawkinsPN SchonlandS HegebartU ComenzoR KastritisE DimopoulosMA JaccardA KlersyC MerliniG New criteria for response to treatment in Immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes J Clin Oncol 2012 30 4541 9 10.1200/JCO.2011.37.761423091105 Search in Google Scholar

98 Jercan A., Ene A., Jurcut R, Draghici M, Badelita S, Dragomir M, Dobrea C, Popescu M, Jardan D, Stoica E, Iacob S, Codita I, Stan C, Coriu D. Clinical characteristics in patients with hereditary amyloidosis with Glu54Gln transthyretin identified in the Romanian population. Orphanet J Rare Dis. 2020; 15:34. JercanA. EneA. JurcutR DraghiciM BadelitaS DragomirM DobreaC PopescuM JardanD StoicaE IacobS CoditaI StanC CoriuD Clinical characteristics in patients with hereditary amyloidosis with Glu54Gln transthyretin identified in the Romanian population Orphanet J Rare Dis 2020 15 34 10.1186/s13023-020-1309-9699331332000831 Search in Google Scholar

99 Caobelli F, Braun M, Haaf P, Wild D, Zellweger MJ. Quantitative (99m)Tc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores. J Nucl Cardiol. 2020; 27:1456–63. CaobelliF BraunM HaafP WildD ZellwegerMJ Quantitative (99m)Tc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores J Nucl Cardiol. 2020 27 1456 63 10.1007/s12350-019-01893-831538322 Search in Google Scholar

100 McVeigh T, Tennyson C. Understanding and recognizing cardiac amyloidosis. JAAPA. 2020; 33:16–20. McVeighT TennysonC Understanding and recognizing cardiac amyloidosis JAAPA. 2020 33 16 20 10.1097/01.JAA.0000697236.11386.3a32941304 Search in Google Scholar

101 Bonderman D, Polzl G, Ablasser K, Agis H, Aschauer S, Grumbach M, Binder C, Dorler J, Duca F, Ebner C, Hacker M, Kain R, Kammerlander A, Koschutnik M, Kroiss A, Mayr A, Nitsche C, Rainer P, Malmqvist S, Schneider M, Schwarz R, Verheyen N, Weber T, Zaruba M, Eslam R, Hulsmann M, Mascherbauer J. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr. 2020; 132:742–61. BondermanD PolzlG AblasserK AgisH AschauerS GrumbachM BinderC DorlerJ DucaF EbnerC HackerM KainR KammerlanderA KoschutnikM KroissA MayrA NitscheC RainerP MalmqvistS SchneiderM SchwarzR VerheyenN WeberT ZarubaM EslamR HulsmannM MascherbauerJ Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement Wien Klin Wochenschr. 2020 132 742 61 10.1007/s00508-020-01781-z773280733270160 Search in Google Scholar

102 Feng D, Edwards W, Oh J, Chandrasekaran K, Grogan M, Martinez M, Syed I, Hughes D, Lust J, Jaffe A, Gertz M, Klarich K. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007; 116:2420–6. FengD EdwardsW OhJ ChandrasekaranK GroganM MartinezM SyedI HughesD LustJ JaffeA GertzM KlarichK Intracardiac thrombosis and embolism in patients with cardiac amyloidosis Circulation. 2007 116 2420 6 10.1161/CIRCULATIONAHA.107.69776317984380 Search in Google Scholar

103 Kapoor P, Thenappan T, Singh E, Kumar S, Greipp P. Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med. 2011; 124:1006–15. KapoorP ThenappanT SinghE KumarS GreippP Cardiac amyloidosis: a practical approach to diagnosis and management Am J Med. 2011 124 1006 15 10.1016/j.amjmed.2011.04.01322017778 Search in Google Scholar

104 Teng C, Li P, Bae J, Pan S, Dixon R, Liu Q. Diagnosis and treatment of thransthyretin-related amyloidosis cardiomyopathy. Clin Cardiol. 2020; 43:1223–31. TengC LiP BaeJ PanS DixonR LiuQ Diagnosis and treatment of thransthyretin-related amyloidosis cardiomyopathy Clin Cardiol. 2020 43 1223 31 10.1002/clc.23434766165832725834 Search in Google Scholar

105 Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Bordeneuve V, Schimdt H, Merlini G. Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. J Am Coll Cardiol. 2015; 66:2451–66. GertzMA BensonMD DyckPJ GroganM CoelhoT CruzM BerkJL BordeneuveV SchimdtH MerliniG Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis J Am Coll Cardiol. 2015 66 2451 66 10.1016/j.jacc.2015.09.07526610878 Search in Google Scholar

106 Algalarrondo V, Dinanian S, Juin C, Chemla D, Bennani S, Sebag C, Plante V, Guludec V, Samuel D, Adams D, Slama M. Prophylactic pacemaker implantation in familial amyloid polyneuropathy. Heart Rhythm 2012; 9:1069–75. AlgalarrondoV DinanianS JuinC ChemlaD BennaniS SebagC PlanteV GuludecV SamuelD AdamsD SlamaM Prophylactic pacemaker implantation in familial amyloid polyneuropathy Heart Rhythm 2012 9 1069 75 10.1016/j.hrthm.2012.02.03322387306 Search in Google Scholar

107 Donellan E, Wazni O, Hanna M, Kanj M, Saliba W, Jaber W. Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis. J Am Heart Assoc. 2020;9 e017335. DonellanE WazniO HannaM KanjM SalibaW JaberW Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis J Am Heart Assoc 2020 9 e017335 10.1161/JAHA.120.017335766072432633203 Search in Google Scholar

108 Donellan E, Wazni O, Hanna M, Saliba W, Jaber W, Kanj M. Primary prevention implantable cardioverter-defibrillators in transthyretin cardiac amyloidosis. Pacing Clin Electrophysiol. 2020; 43:1401–3. DonellanE WazniO HannaM SalibaW JaberW KanjM Primary prevention implantable cardioverter-defibrillators in transthyretin cardiac amyloidosis Pacing Clin Electrophysiol. 2020 43 1401 3 10.1111/pace.1402332725816 Search in Google Scholar

109 Priori S, Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliot P, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck K, Madrid A, Nikolaou N, Norekval T, Spaulding C, Veldhuisen D. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac Death. The Task Force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology. Eur Heart J. 2015; 36:2793–867. PrioriS LundqvistC MazzantiA BlomN BorggrefeM CammJ ElliotP FitzsimonsD HatalaR HindricksG KirchhofP KjeldsenK KuckK MadridA NikolaouN NorekvalT SpauldingC VeldhuisenD 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac Death. The Task Force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology Eur Heart J. 2015 36 2793 867 10.1093/eurheartj/ehv31626320108 Search in Google Scholar

110 Tan N, Mohsin Y, Hodge D, Lacy M, Packer D, Dispenzieri A, Grogan M, Asirvatham S, Madhavan M, McLEOD C. Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol. 2016; 27:1167–73. TanN MohsinY HodgeD LacyM PackerD DispenzieriA GroganM AsirvathamS MadhavanM McLEODC Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis J Cardiovasc Electrophysiol. 2016 27 1167 73 10.1111/jce.1304627422772 Search in Google Scholar

111 Spoladore R, Falasconi G, Marcatti M, Maio S, Fiore G, Slavich M, Margonato A, Turco A, Fragasso G. Advances in pharmacotherapy for cardiac amyloidosis. Expert Opin Pharmacother. 2020;31:1–13. SpoladoreR FalasconiG MarcattiM MaioS FioreG SlavichM MargonatoA TurcoA FragassoG Advances in pharmacotherapy for cardiac amyloidosis Expert Opin Pharmacother 2020 31 1 13 10.1080/14656566.2020.183615933043721 Search in Google Scholar

112 Kastritis E, Arnulf B, Leieu X, Zamagni E. A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis. Blood. 2016;128: 646. KastritisE ArnulfB LeieuX ZamagniE A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis Blood 2016 128 646 10.1182/blood.V128.22.646.646 Search in Google Scholar

113 Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136:71–80. PalladiniG KastritisE MaurerMS ZonderJ MinnemaMC WechalekarAD JaccardA LeeHC BummaN KaufmanJL MedvedovaE KovacsovicsT RosenzweigM SanchorawalaV QinX VaseySY WeissBM VermeulenJ MerliniG ComenzoRL Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA Blood 2020 136 71 80 10.1182/blood.2019004460733289732244252 Search in Google Scholar

114 Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan 3rd TH, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O. Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139:431–43. SolomonSD AdamsD KristenA GroganM Gonzalez-DuarteA MaurerMS MerliniG DamyT SlamaMS BrannaganTH3rd DispenzieriA BerkJL ShahAM GargP VaishnawA KarstenV ChenJ GollobJ VestJ SuhrO Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis Circulation 2019 139 431 43 10.1161/CIRCULATIONAHA.118.03583130586695 Search in Google Scholar

115 Gertz M, Comenzo R, Landau H, Sanchorawala V, Weiss B, Zonder J, Walling J, Kinney G, Koller M, Schenk D, Guthrie S, Liu E, Liedtke M. NEOD001 demonstrates organ biomarker response in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion cohort of a phase ½ study. Blood. 2016; 128:644. GertzM ComenzoR LandauH SanchorawalaV WeissB ZonderJ WallingJ KinneyG KollerM SchenkD GuthrieS LiuE LiedtkeM NEOD001 demonstrates organ biomarker response in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion cohort of a phase ½ study Blood 2016 128 644 10.1182/blood.V128.22.644.644 Search in Google Scholar

116 Castano A, Helmke S, Alvarez J, Delisle S, Maurer M. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail. 2012; 18:315–9. CastanoA HelmkeS AlvarezJ DelisleS MaurerM Diflunisal for ATTR cardiac amyloidosis Congest Heart Fail. 2012 18 315 9 10.1111/j.1751-7133.2012.00303.x372715322747647 Search in Google Scholar

117 Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, Connors LH, Vellanki N, Hellawell J, Siddiqi OK, Fox J, Maurer MS, Ruberg FL. Stabilization of cardiac function with Diflunisal in transthyretin (ATTR) cardiac amyloidosis. J Card Fail. 2020;26:753–9 LohrmannG PipilasA MussinelliR GopalDM BerkJL ConnorsLH VellankiN HellawellJ SiddiqiOK FoxJ MaurerMS RubergFL Stabilization of cardiac function with Diflunisal in transthyretin (ATTR) cardiac amyloidosis J Card Fail 2020 26 753 9 10.1016/j.cardfail.2019.11.024775887231805416 Search in Google Scholar

118 Maurer M, Schwartz J, Gundapaneni B, Elliot P, Merlini G, Cruz M, Kristen A, Grogan M, Witteles R, Damy T, Drachman B, Shah S, Hanna M, Judge D, Barsdorf A, Huber P, Patterson T, Riley S, Schumacher J, Stewart M, Sultan M, Rapezzi C. ATTR-ACT study investigators: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007–16. MaurerM SchwartzJ GundapaneniB ElliotP MerliniG CruzM KristenA GroganM WittelesR DamyT DrachmanB ShahS HannaM JudgeD BarsdorfA HuberP PattersonT RileyS SchumacherJ StewartM SultanM RapezziC ATTR-ACT study investigators: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy N Engl J Med 2018 379 1007 16 10.1056/NEJMoa180568930145929 Search in Google Scholar

119 Endo J, Sano M, Izumyia Y, Tsujita K, Nakamura K, Tahara N, Kuwahara K, Inomata T, Ueda M, Sekijima Y, Ando Y, Tsutsui H, Isobe M, Fukuda K. A statement on the appropriate administration of Tafamidis in patients with transthyretin cardiac amyloidosis. Circ J 2019;84: 15–7. EndoJ SanoM IzumyiaY TsujitaK NakamuraK TaharaN KuwaharaK InomataT UedaM SekijimaY AndoY TsutsuiH IsobeM FukudaK A statement on the appropriate administration of Tafamidis in patients with transthyretin cardiac amyloidosis Circ J 2019 84 15 7 10.1253/circj.CJ-19-081131735731 Search in Google Scholar

120 Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang, CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan 3rd TH, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21. AdamsD Gonzalez-DuarteA O’RiordanWD YangCC UedaM KristenAV TournevI SchmidtHH CoelhoT BerkJL LinKP VitaG AttarianS Plante-BordeneuveV MezeiMM CampistolJM BuadesJ BrannaganTH3rd KimBJ OhJ ParmanY SekijimaY HawkinsPN SolomonSD PolydefkisM DyckPJ GandhiPJ GoyalS ChenJ StrahsAL NochurSV SweetserMT GargPP VaishnawAK GollobJA SuhrOB Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis N Engl J Med 2018 379 11 21 10.1056/NEJMoa171615329972753 Search in Google Scholar

121 Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheiberg M, Brannagan 3rd TH, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31. BensonMD Waddington-CruzM BerkJL PolydefkisM DyckPJ WangAK Plante-BordeneuveV BarrosoFA MerliniG ObiciL ScheibergM BrannaganTH3rd LitchyWJ WhelanC DrachmanBM AdamsD HeitnerSB ConceicaoI SchmidtHH VitaG CampistolJM GamezJ GorevicPD GaneE ShahAM SolomonSD MoniaBP HughesSG KwohTJ McEvoyBW JungSW BakerBF AckermannEJ GertzMA CoelhoT Inotersen treatment for patients with hereditary transthyretin amyloidosis N Engl J Med 2018 379 22 31 10.1056/NEJMoa171679329972757 Search in Google Scholar

122 Scully PR, Patel KP, Treibel TA, Thornton GD, Hughes RK, Chadalavada S, Katsoulis M, Hartman N, Fontana M, Pugliese F, Sabharwal N, Newton JD, Kelion A, Ozkor M, Kennon S, Mullen M, Lloyd G, Menezes LJ, Hawkins PN, Moon JC. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41:2759–67. ScullyPR PatelKP TreibelTA ThorntonGD HughesRK ChadalavadaS KatsoulisM HartmanN FontanaM PuglieseF SabharwalN NewtonJD KelionA OzkorM KennonS MullenM LloydG MenezesLJ HawkinsPN MoonJC Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation Eur Heart J 2020 41 2759 67 10.1093/eurheartj/ehaa170739532932267922 Search in Google Scholar

123 Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, Wollenweber T, Ahmed N, Thornton GD, Kelion AD, Sabharwal N, Newton JD, Ozkor M, Kennon S, Mullen M, Lloyd G, Fontana M, Hawkins PN, Pugliese F, Menezes LJ, Moon JC, Mascherbauer J, Treibel TA. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol. 2021;77:128–39. NitscheC ScullyPR PatelKP KammerlanderAA KoschutnikM DonaC WollenweberT AhmedN ThorntonGD KelionAD SabharwalN NewtonJD OzkorM KennonS MullenM LloydG FontanaM HawkinsPN PuglieseF MenezesLJ MoonJC MascherbauerJ TreibelTA Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis J Am Coll Cardiol 2021 77 128 39 10.1016/j.jacc.2020.11.006780526733181246 Search in Google Scholar

124 Koike H, Katsuno M. Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol Ther 2020; 9:317–33. KoikeH KatsunoM Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies Neurol Ther 2020 9 317 33 10.1007/s40120-020-00210-7750025132948978 Search in Google Scholar